History

Background: Study role important in understand and treat the pathology of obesity and NAFLD to prevent metabolic syndrome. Treatments for obesity and NAFLD commonly include lifestyle management through weight loss, dietary restriction, exercise, etc. Objective: This study was aim to investigate the role of TTR, in the non-alcoholic fatty liver disease and nonalcoholic fatty liver disease (NAFLD) among the patients with type 2 diabetes mellitus (T2DM). The study will be, done at the National Diabetes Center of Mustansiriyah University. One hundred thirty-five subjects with age ranged from (35-65) years were in the serum TTR; concentrations were measured by radioimmunoassay in 150 patients. Diabetic patients were chosen from almost diagnosed patients on follow up visits to the center. The NAFLD diabetic patients were chosen according to clinical features of liver diseases had liver ultrasonic appearance and abnormal liver function tests. Patients were distributed; three study groups as following: Group one: 50 patients, T2DM with NAFLD Group two: 50 patients, T2DM without NAFLD; Group three 50 healthy controls. Results: There was a significant increase it was discovered that there is a positive relationship between transthyretin and that this relationship is statistically significant FSG HbA1c, LDL VLDL, were found to be positively correlated with. Transthyretin were found to be positively correlated at a moderate effect size and echogenicity.it is decrease HDL level found negative correlated with HDL. Conclusions: This study found that diabetic patients with NAFLD had a significant increase in serum levels of TG, LDL, and VLDL as compared to T2D, and lower levels of HDL. Treatment options for NAFLD patients include lifestyle intervention and weight loss and anti-diabetic drugs that target IR or bring benefits of weight loss have yielded positive results. More clinical data is needed to make a firm recommendation about the optimal treatment.